Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sanofi - American Depositary Shares (NQ:SNY)

50.89 +0.70 (+1.39%)
Streaming Delayed Price Updated: 11:05 AM EDT, Aug 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sanofi - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
37 38 Next >
Top 3 Health Care Stocks That May Keep You Up At Night In Q1
 
Via Benzinga
Amgen And Kyowa Kirin's Rocatinlimab Reduces Eczema Severity In Phase 3 Study
Amgen and Kyowa Kirin's rocatinlimab showed strong efficacy in Phase 3 trials for atopic dermatitis, achieving key endpoints in IGNITE and SHUTTLE studies. 
Via Benzinga
Dupixent® (dupilumab) Late-Breaking Positive Pivotal Data in Bullous Pemphigoid Presented at AAD
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Eli Lilly's Single Monthly Maintenance Shot Of Eczema Drug Shows Completely Clear Skin At 3 Years In 50% Of Trial Patients
Eli Lilly's Ebglyss showed sustained eczema relief, with 50% achieving full skin clearance and 87% maintaining near-clear skin over three years. 
Via Benzinga
Is NASDAQ:SNY suited for dividend investing?
Is SANOFI-ADR (NASDAQ:SNY) suited for dividend investing? 
Via Chartmill
How Is The Market Feeling About Sanofi?
 
Via Benzinga
How Is The Market Feeling About Sanofi?
 
Via Benzinga
Price Over Earnings Overview: Sanofi
 
Via Benzinga
Apogee Therapeutics' Investigational Atopic Dermatitis Potential Shows Strong Tolerability, Extended Half-Life in Early Trial
Apogee's APG990 Phase 1 data show a 60-day half-life and strong tolerability, supporting long-interval dosing. A 2025 trial will compare APG279 to Dupixent. 
Via Benzinga
For those who appreciate value investing, SANOFI-ADR (NASDAQ:SNY) is a compelling option with its solid fundamentals.
When you look at SANOFI-ADR (NASDAQ:SNY), it's hard to ignore the strong fundamentals, especially considering its likely undervaluation. 
Via Chartmill
Is SANOFI-ADR (NASDAQ:SNY) Ready to Break Out of Its Range?
Investors are keeping a close eye on SANOFI-ADR (NASDAQ:SNY) as it boasts an impressive technical rating of 8 out of 10, signaling a possible breakout. 
Via Chartmill
Novavax Lands Wall Street 'Buy' Rating After Q4 Results, Retail Bulls Eye More Upside On Sanofi Partnership
The company expects to generate $300 million to $350 million in adjusted licensing, royalties, and other revenue in 2025. 
Via Stocktwits
Moderna Tumbles As RFK Jr. Reportedly Mulls Pulling $590 Million In Bird Flu Funds
Moderna is under pressure as two of its vaccines hit potential snags. 
Via Investor's Business Daily
Novavax Reports Smaller Q4 Loss, Shifts Focus From Commercializing COVID-19 Vaccine To Maximize Value
Novavax reported Q4 sales of $88.31 million, beating estimates despite a decline. The company shifts focus to partnerships and expects up to $350 million in 2025 revenue. 
Via Benzinga
Regeneron: Is It the Perfect Biotech Stock for Value and Growth?
Regeneron is trading at historically low valuations as its Dupixent blockbuster drug could get a 30% increase in TAM if the FDA approves its use in COPD. 
Via MarketBeat
Novavax Retail Traders Stay Bullish Ahead Of Q4 Print Even As RFK Jr's HHS Leadership Causes Ripples
Kennedy, a longtime vaccine skeptic, now oversees HHS decisions that could impact vaccine makers, making his leadership a wild card for Novavax. 
Via Stocktwits
Sanofi/Teva Unveil New Detailed Data For Duvakitug Study Supporting Overall Efficacy For Common Inflammatory Bowel Disease
Teva and Sanofi's duvakitug showed promising results in a Phase 2b study for ulcerative colitis and Crohn's disease, with plans for a Phase 3 trial in 2025. 
Via Benzinga
Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 Reinforcing Best-in-Class Potential of Duvakitug (Anti-TL1A) in Ulcerative Colitis and Crohn’s Disease
Teva hosting investor call Monday, February 24 at 8:00 a.m. U.S. ET 
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
FDA Approves Sanofi's Merilog As First Rapid-Acting Insulin Biosimilar Product For Diabetes
Sanofi's Merilog wins FDA approval as the first rapid-acting insulin biosimilar to Novolog, offering a new option for diabetes management. 
Via Benzinga
Sanofi/Johnson & Johnson Partnered Vaccine Against Bacterial Sepsis Flunks Late-Stage Study
Sanofi and J&J halted a phase 3 E. coli vaccine trial due to insufficient efficacy. Sanofi's Q4 2024 IFRS EPS dropped by €0.15 following a $250M charge. 
Via Benzinga
Arcutis Soared In 2024, Blazing Trails In Dermatology. Why Its CEO Eyes Bigger Gains.
The company won three FDA approvals over the past two years. Now, it's angling for two new approvals in 2025. 
Via Investor's Business Daily
Why Regeneron Pharmaceuticals Stock Topped the Market on Tuesday
Via The Motley Fool
Sanofi Buys Back ~$3 Billion In Shares From L'Oréal: Details
Sanofi has purchased 2.3% of its shares from L'Oréal SA as part of its share repurchase program. The €3 billion deal involves acquiring 29.6 million shares at €101.50 each, with cancellation expected... 
Via Benzinga
Sanofi (SNY) Q4 2024 Earnings Call Transcript
SNY earnings call for the period ending December 31, 2024. 
Via The Motley Fool
Topics Earnings
Teva's Duvakitug Set To Shake Up IBD Treatment, Analyst Highlights Competitive Data
Piper Sandler analyst maintains an Overweight rating on Teva, citing positive feedback on duvakitug's potential in treating IBD. 
Via Benzinga
Moderna, Pfizer Surge Amid CDC-WHO Split And Bird Flu; RFK Jr. Nomination Looms — A Recipe For The Perfect Storm?
The Centers for Disease Control and Prevention abruptly ordered its staff to cease all collaboration with the World Health Organization on Monday, marking a dramatic acceleration of President Donald... 
Via Benzinga
Topics Government
Sanofi Genzyme Facility Draws FDA Criticism Over Alleged Quality Lapses
FDA issues warning letter to Sanofi over its Genzyme facility, citing process deviations, equipment issues, and quality oversight lapses. 
Via Benzinga
AI Drug Discovery Startups: Analysis Of Exscientia’s Acquisition By Recursion
Exscientia is a European player looking to make a difference in the AI-drug discovery market. Like other players, it has an interesting story to tell. After a brief listing on the stock market,... 
Via Talk Markets
Topics Artificial Intelligence Stocks / Equities
Earnings Scheduled For January 30, 2025
 
Via Benzinga
Why Verona Pharma, A Triple-Digit Gainer In 2024, Surged Another 22% This Week
The company is working to launch its COPD treatment more broadly. The drug is a non-steroidal nebulizer. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 9
...
37 38 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.